Recent Publications by Seattle Genetics: |
Potent antibody drug conjugates for cancer therapy.
Significant progress has been made in the past few years in the area of... | 1st October, 2009
| Seattle Genetics, Inc., 21823 30th Dr. SE, Bothell, WA 98021, United
| Curr Opin Chem Biol. 2009 Jun;13(3):235-44. Epub 2009 May 4.
DOI Direct Link |
Blocking of CD27-CD70 pathway by anti-CD70 antibody ameliorates joint disease in murine collagen-induced arthritis.
Rheumatoid arthritis (RA) is characterized by inflammation and cellular... | 24th September, 2009
| Department of Preclinical Therapeutics, Seattle Genetics, Bothell,
| J Immunol. 2009 Sep 15;183(6):3770-7. Epub 2009 Aug 26.
DOI Direct Link |
The pharmacologic basis for antibody-auristatin conjugate activity.
Antibody-drug conjugates (ADCs) made with auristatin antimitotic agents... | 22nd September, 2009
| Seattle Genetics, Inc., 21823 30th Drive SE, Bothell, WA 98021, USA.
| J Pharmacol Exp Ther. 2009 Sep;330(3):932-8. Epub 2009 Jun 4.
DOI Direct Link |
Targeting CD30/CD30L in Oncology and Autoimmune and Inflammatory Diseases.
The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153,... | 18th September, 2009
| Department of Preclinical Therapeutics, Seattle Genetics, Inc, 21823 30th
| Adv Exp Med Biol. 2009;647:174-85.
DOI Direct Link |
Targeting CD70 for Human Therapeutic Use.
Expression of CD70, a member of the tumor necrosis factor superfamily, is... | 18th September, 2009
| Department of Preclinical Therapeutics, Seattle Genetics, Inc., Bothell,
| Adv Exp Med Biol. 2009;647:108-19.
DOI Direct Link |
Targeting of BAFF and APRIL for Autoimmunity and Oncology.
BLyS and APRIL are tumor necrosis factor superfamily members shown to be... | 18th September, 2009
| Seattle Genetics, Inc., 21823-30th Drive SE, Bothell, WA, 98021, USA,
| Adv Exp Med Biol. 2009;647:52-63.
DOI Direct Link |
Therapeutic Interventions Targeting CD40L (CD154) and CD40: The Opportunities and Challenges.
CD40 was originally identified as a receptor on B-cells that delivers... | 18th September, 2009
| Department of Preclinical Therapeutics, Seattle Genetics Inc., 21823 30th
| Adv Exp Med Biol. 2009;647:8-36.
DOI Direct Link |
Overview of TNF Superfamily: A Chest Full of Potential Therapeutic Targets.
Since the discovery of tumor necrosis factor TNFalpha about 25 years ago,... | 18th September, 2009
| Department of Preclinical Therapeutics, Seattle Genetics, Inc., 21823 30th
| Adv Exp Med Biol. 2009;647:1-7.
DOI Direct Link |
Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues.
Antibody-drug conjugates (ADCs) were prepared with potent camptothecin... | 2nd September, 2009
| Seattle Genetics, Inc., 21823 30th Drive SE, Bothell, Washington 98021,
| Bioconjug Chem. 2009 Jun;20(6):1242-50.
DOI Direct Link |
Novel antibody-based therapeutic agents targeting CD70: a potential approach for treating Waldenstrom's macroglobulinemia.
Targeting leukocyte differentiation antigens is a validated approach to... | 3rd July, 2009
| Department of Preclinical Therapeutics, Seattle Genetics, Inc, Bothell, WA
| Clin Lymphoma Myeloma. 2009 Mar;9(1):90-3.
DOI Direct Link |
Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system.
Cytotoxic agents streptonigrin and 17-amino-geldanamycin were linked to... | 30th June, 2009
| Seattle Genetics,
| Bioorg Med Chem Lett. 2009 May 15;19(10):2650-3. Epub 2009 Apr 5.
DOI Direct Link |
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.
Despite major advances in the treatment of non-Hodgkin lymphoma (NHL),... | 3rd June, 2009
| Department of Preclinical Therapeutics, Seattle Genetics, Bothell, WA
| Blood. 2009 Apr 30;113(18):4352-61. Epub 2009 Jan 15.
DOI Direct Link |
Meeting report: drug carriers in medicine and biology.
Despite major advances in the treatment of non-Hodgkin lymphoma (NHL),... | 24th March, 2009
| Seattle Genetics,
| Mol Pharm. 2009 Jan-Feb;6(1):82-5.
DOI Direct Link |
Preclinical characterization of SGN-70, a humanized antibody directed against CD70.
PURPOSE: CD70 (CD27L) is a member of the tumor necrosis factor family... | 6th February, 2009
| Seattle Genetics, Inc., Bothell, Washington 98021, USA.
| Clin Cancer Res. 2008 Dec 1;14(23):7763-72.
DOI Direct Link |
Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40.
SGN-40 is a therapeutic antibody targeting CD40, which induces potent... | 31st January, 2009
| Department of Preclinical Therapeutics, Seattle Genetics Inc., Seattle, WA
| Br J Cancer. 2009 Jan 13;100(1):113-7. Epub 2008 Dec 9.
DOI Direct Link |
